Teva Pharmaceutical Industries Limited Q3 2025 Earnings Recap

TEVA Q3 2025 November 6, 2025

Get alerts when TEVA reports next quarter

Teva Pharmaceutical Industries reported robust growth in Q3 2025, achieving its 11th consecutive quarter of revenue increase, with total revenue up 3% year-over-year and adjusted EBITDA rising 6%.

Earnings Per Share Beat

$0.78 vs $0.68 est.

+14.7% surprise

Revenue Beat

4480000000 vs 4454812440 est.

+0.6% surprise

Market Reaction

1-Day -2.0%

5-Day +4.42%

30-Day +16.76%

See TEVA alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue reached $4.5 billion, driven by a 33% increase in innovative product sales, totaling over $800 million.
AUSTEDO's revenue grew 38% year-over-year, surpassing $600 million for the first time, and reaffirmed a 2027 revenue target of $2.5 billion.
UZEDY experienced a 24% revenue increase with a 119% rise in TRx, confirming long-term peak sales ambitions of $1.5 billion to $2 billion.
Free cash flow exceeded $0.5 billion, and net debt to EBITDA improved to below 3x, marking a significant financial milestone for the firm.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit TEVA on AllInvestView.

Previous Q2 2025